LZIC: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: LZIC

NCBI ID: G84328

LZIC

LZIC: A Potential Drug Target Or Biomarker for Various Diseases

LZIC (LZIC variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the superfamily of RNA-binding proteins, known as HNRNA-proteins. LZIC is characterized by its ability to interact with specific DNA sequences, as well as its role in the regulation of gene expression.

Recent studies have suggested that LZIC may be a drug target or biomarker for a variety of diseases. One potential mechanism by which LZIC could be targeted by drugs is its role in the regulation of cellular processes that are important for disease development, such as cell proliferation, migration, and apoptosis. LZIC has been shown to play a role in the regulation of cell cycle progression, and it is possible that drugs that target its activity could be effective in treating various types of cancer.

Another potential mechanism by which LZIC could be used as a biomarker is its ability to interact with specific DNA sequences. This property has led to the development of genetic assays that can be used to detect changes in the expression of genes that are associated with disease. For example, LZIC has been shown to interact with the gene encoding the protein p53, which is a well-known regulator of DNA damage repair. This interaction suggests that LZIC may be a useful biomarker for diseases that are characterized by DNA damage, such as cancer.

In addition to its potential as a drug target or biomarker, LZIC is also of interest as a potential therapeutic agent. LZIC has been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis, such as cell migration and the regulation of ion and water balance. Drugs that target LZIC activity may be effective in treating various types of diseases, such as neurodegenerative disorders and chronic pain.

Overall, LZIC is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: Leucine Zipper And CTNNBIP1 Domain Containing

The "LZIC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LZIC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets